Efficacy of Entecavir and Adefovir Combination Therapy for Patients with Lamivud

StephenW

Dig Dis Sci. 2011 Dec 2. [Epub ahead of print]

Efficacy of Entecavir and Adefovir Combination Therapy for Patients with
Lamivudine- and Entecavir-Resistant Chronic Hepatitis B.

Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S.

http://www.ncbi.nlm.nih.gov/pubmed/22134785

Source

Department of Internal Medicine, College of Medicine, Kyung Hee University,
149 Sangil-dong, Gangdong-gu, Seoul, 134-727, Korea.

Abstract

BACKGROUND:

The optimal treatment of patients with chronic hepatitis B (CHB) who
develop resistance to both lamivudine (LMV) and entecavir (ETV) after
sequential monotherapy of LMV and ETV remains little known.

METHODS:

We evaluated the efficacy of entecavir (ETV) plus adefovir dipivoxil (ADV)
combination therapy for patients with resistance to LMV and ETV. We
reviewed the medical records of 12 patients, and treated all 12 patients
with ETV plus ADV combination therapy for at least 18 months. Quantitative
hepatitis B virus (HBV) DNA levels, serologic markers, and hepatic panel
values were monitored at baseline and 3-month intervals thereafter for 18
months.

RESULTS:

The baseline mean serum HBV DNA level was 7.26 ± 1.11 log(10) copies/ml.
The mean reductions in serum HBV DNA levels from baseline to 3, 6, 9, 12,
15, and 18 months were -1.98 ± 1.03, -2.87 ± 1.02, -3.32 ± 1.10, -3.92
± 1.30, -4.36 ± 1.22, and -4.57 ± 1.18 log(10) copies/ml, respectively.
Complete virological response (HBV DNA of <2 log(10) copies/ml) at 6, 12,
and 18 months was observed in 1 (8.3%), 4 (33.3%), and 6 (50.0%) patients,
respectively. The 2 patients with baseline HBV DNA of <6 log(10) copies/ml
achieved complete virological response at 18 months, while 4 of 10 patients
with baseline HBV DNA of >=6 log(10) copies/ml achieved complete virological
response at 18 months. None of the 12 patients experienced virological
breakthrough during follow-up.

CONCLUSIONS:

ETV plus ADV combination therapy effectively reduced serum HBV DNA levels
in patients with CHB who developed resistance to both LMV and ETV.
Additional long-term studies are needed to assess the effect of long-term
treatment with these drugs.

StephenW

挖掘DIS科学。 2011年12月2日。 [检索提前打印]

恩替卡韦和阿德福韦联合治疗的患者的疗效观察
拉米夫定和恩替卡韦耐药慢性乙型肝炎

全度妍炜，新惠普，李骥，珠KR，茶JM，园林俊杰，林巨，林K金S.

http://www.ncbi.nlm.nih.gov/pubmed/22134785

来源

内科医学系，医学院，庆熙大学，
149上一洞，江东区，汉城134-727，韩国。

摘要

背景：

该患者的最佳治疗慢性乙型肝炎（CHB）
耐拉米夫定（LMV）和恩替卡韦（ETV）后
连续LMV和ETV单药治疗仍然鲜为人知。

方法：

我们评估了恩替卡韦（ETV），加上阿德福韦酯（ADV）的疗效
抗LMV和ETV患者的联合治疗。我们
审查了12例患者的病历，并处理了所有12名患者
教育电视加ADV联合治疗至少18个月。定量
B型肝炎病毒（HBV）DNA水平，血清学标志物，肝面板
值分别在基线和3个月的时间间隔监测此后18
个月。

结果：

基线平均血清HBV DNA水平为7.26 ± 1.11log（10）拷贝/ ml。
平均血清HBV DNA水平从基线减少到3，6，9，12，
15日和18月分别为-1.98 ± 1.03，-2.87 ± 1.02，-3.32 ± 1.10，-3.92
± 1.30，-4.36 ± 1.22和-4.57 ± 1.18log（10）拷贝/ ml，分别。
完全病毒学应答（HBV DNA <2log（10）拷贝/ ml）6，12，
18个月，观察1（8.3％），4（33.3％）和6例（50.0％），
。与基线HBV DNA <6log（10）拷贝/毫升的2例
而4 /10例患者取得完全病毒学应答，在18个月
与基线HBV DNA >=？6log（10）拷贝/ ml取得了完整的病毒学
在18个月的响应。 12例患者没有经历病毒学
突破时跟进。